Du L, Zhu S, Lu Z, et al. Ascitic cholesterol is superior to serum-ascites albumin gradient in the detection of non-portal hypertensive ascites and the diagnosis of mixed ascites. Aliment Pharmacol Ther. 2019;49(1):91–8.
Article
CAS
PubMed
Google Scholar
Stukan M. Drainage of malignant ascites: patient selection and perspectives. Cancer Manag Res. 2017;9:115–30.
Article
PubMed
PubMed Central
Google Scholar
Zhu S, Du L, Xu D, et al. Ascitic fluid total protein, a useful marker in non-portal hypertensive ascites. J Gastroenterol Hepatol. 2020;35(2):271–7.
Article
CAS
PubMed
Google Scholar
Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol: Off J Eur Soc Med Oncol. 2007;18(5):945–9.
Article
CAS
Google Scholar
Costa-Pinheiro P, Montezuma D, Henrique R, Jeronimo C. Diagnostic and prognostic epigenetic biomarkers in cancer. Epigenomics. 2015;7(6):1003–15.
Article
CAS
PubMed
Google Scholar
Otani K, Li X, Arakawa T, Chan FK, Yu J. Epigenetic-mediated tumor suppressor genes as diagnostic or prognostic biomarkers in gastric cancer. Expert Rev Mol Diagn. 2013;13(5):445–55.
Article
CAS
PubMed
Google Scholar
West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Investig. 2014;124(1):30–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Feng W, Zhang B, Cai D, Zou X. Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer. Cancer Lett. 2014;347(2):183–90.
Article
CAS
PubMed
Google Scholar
Mielcarek M, Zielonka D, Carnemolla A, Marcinkowski JT, Guidez F. HDAC4 as a potential therapeutic target in neurodegenerative diseases: a summary of recent achievements. Front Cell Neurosci. 2015;9:42.
Article
PubMed
PubMed Central
Google Scholar
Ganai SA. Summa of erasers of histone acetylation with special emphasis on classical histone deacetylases (HDACs). In: Ganai SA, editor. Histone deacetylase inhibitors in combinatorial anticancer therapy. Springer: Singapore; 2020. p. 67–74.
Chapter
Google Scholar
Ganai SA. Strong involvement of classical histone deacetylases and mechanistically distinct Sirtuins in bellicose cancers. In: Ganai SA, editor. Histone deacetylase inhibitors in combinatorial anticancer therapy. Springer: Singapore; 2020. p. 75–95.
Chapter
Google Scholar
Azad NS, El-Khoueiry A, Yin J, et al. Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study. Oncotarget. 2017;8(21):35326–38.
Article
PubMed
PubMed Central
Google Scholar
Connolly RM, Li H, Jankowitz RC, et al. Combination epigenetic therapy in advanced breast cancer with 5-azacitidine and entinostat: a Phase II National Cancer Institute/Stand Up to Cancer Study. Clin Cancer Res: Off J Am Assoc Cancer Res. 2017;23(11):2691–701.
Article
CAS
Google Scholar
Jespersen H, Olofsson Bagge R, Ullenhag G, et al. Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study. BMC Cancer. 2019;19(1):415.
Article
CAS
PubMed
PubMed Central
Google Scholar
Juergens RA, Wrangle J, Vendetti FP, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011;1(7):598–607.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pili R, Quinn DI, Hammers HJ, et al. Immunomodulation by entinostat in renal cell carcinoma patients receiving high-dose interleukin 2: a multicenter, single-arm, phase I/II trial (NCI-CTEP#7870). Clin Cancer Res: Off J Am Assoc Cancer Res. 2017;23(23):7199–208.
Article
CAS
Google Scholar
Prebet T, Sun Z, Figueroa ME, et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. J Clin Oncol: Off J Am Soc Clin Oncol. 2014;32(12):1242–8.
Article
CAS
Google Scholar
Witta SE, Jotte RM, Konduri K, et al. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol: Off J Am Soc Clin Oncol. 2012;30(18):2248–55.
Article
CAS
Google Scholar
Mariadason JM. HDACs and HDAC inhibitors in colon cancer. Epigenetics. 2008;3(1):28–37.
Article
PubMed
Google Scholar
Ozeki N, Hakiri S, Tateyama H, Yokoi K, Chen-Yoshikawa T. Primary peritoneal carcinoma with late-phase pulmonary metastases: a case report. Surg Case Rep. 2019;5(1):194.
Article
PubMed
PubMed Central
Google Scholar
Liu HJ, Qin Y, Zhao ZH, et al. Lentinan-functionalized selenium nanoparticles target tumor cell mitochondria via TLR4/TRAF3/MFN1 pathway. Theranostics. 2020;10(20):9083–99.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wei H, Qin S, Yin X, et al. Endostar inhibits ascites formation and prolongs survival in mouse models of malignant ascites. Oncol Lett. 2015;9(6):2694–700.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yang W, Wightman R, Meyerowitz EM. Cell cycle control by nuclear sequestration of CDC20 and CDH1 mRNA in plant stem cells. Mol Cell. 2017;68(6):1108–19.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wong K, van der Weyden L, Schott CR, et al. Cross-species genomic landscape comparison of human mucosal melanoma with canine oral and equine melanoma. Nat Commun. 2019;10(1):353.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chen X, Wang Y, Zang W, Du Y, Li M, Zhao G. miR-194 targets RBX1 gene to modulate proliferation and migration of gastric cancer cells. Tumour Biol: J Int Soc Oncodev Biol Med. 2015;36(4):2393–401.
Article
CAS
Google Scholar
Li Y, Jin K, Bunker E, et al. Structural basis of the phosphorylation-independent recognition of cyclin D1 by the SCF(FBXO31) ubiquitin ligase. Proc Natl Acad Sci USA. 2018;115(2):319–24.
Article
CAS
PubMed
Google Scholar
Edelman MJ, Redman MW, Albain KS, et al. SWOG S1400C (NCT02154490)—a phase II study of palbociclib for previously treated cell cycle gene alteration-positive patients with stage IV squamous cell lung cancer (lung-MAP SUBSTUDY). J Thoracic Oncol: Off Publ Int Assoc Study Lung Cancer. 2019;14(10):1853–9.
Article
CAS
Google Scholar
Ogiwara H, Sasaki M, Mitachi T, et al. Targeting p300 addiction in CBP-deficient cancers causes synthetic lethality by apoptotic cell death due to abrogation of MYC expression. Cancer Discov. 2016;6(4):430–45.
Article
CAS
PubMed
Google Scholar
Jung S, Moon HI, Lee BS, et al. Anti-cancerous effect of cis-khellactone from Angelica amurensis through the induction of three programmed cell deaths. Oncotarget. 2018;9(24):16744–57.
Article
PubMed
PubMed Central
Google Scholar
McComb S, Cessford E, Alturki NA, et al. Type-I interferon signaling through ISGF3 complex is required for sustained Rip3 activation and necroptosis in macrophages. Proc Natl Acad Sci USA. 2014;111(31):E3206-3213.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ding Y, He C, Lu S, et al. MLKL contributes to shikonin-induced glioma cell necroptosis via promotion of chromatinolysis. Cancer Lett. 2019;467:58–71.
Article
CAS
PubMed
Google Scholar
Ying Y, Padanilam BJ. Regulation of necrotic cell death: p53, PARP1 and cyclophilin D-overlapping pathways of regulated necrosis? Cell Mol Life Sci: CMLS. 2016;73(11–12):2309–24.
Article
CAS
PubMed
Google Scholar
Ma Y, Fei L, Zhang M, et al. Lamin B2 binding to minichromosome maintenance complex component 7 promotes non-small cell lung carcinogenesis. Oncotarget. 2017;8(62):104813–30.
Article
PubMed
PubMed Central
Google Scholar
Yamamoto M, Jin C, Hata T, et al. MUC1-C integrates chromatin remodeling and PARP1 activity in the DNA damage response of triple-negative breast cancer cells. Cancer Res. 2019;79(8):2031–41.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yan C, Gong L, Chen L, et al. PHB2 (prohibitin 2) promotes PINK1-PRKN/Parkin-dependent mitophagy by the PARL-PGAM5-PINK1 axis. Autophagy. 2020;16(3):419–34.
Article
CAS
PubMed
Google Scholar
Hassannia B, Vandenabeele P, Vanden BT. Targeting ferroptosis to iron out cancer. Cancer Cell. 2019;35(6):830–49.
Article
CAS
PubMed
Google Scholar
Reina S, Guarino F, Magri A, De Pinto V. VDAC3 as a potential marker of mitochondrial status is involved in cancer and pathology. Front Oncol. 2016;6:264.
Article
PubMed
PubMed Central
Google Scholar
Chuang YL, Hsu CY. Changes in mitochondrial energy utilization in young and old worker honeybees (Apis mellifera). Age. 2013;35(5):1867–79.
Article
CAS
PubMed
Google Scholar
Radulovich N, Pham NA, Strumpf D, et al. Differential roles of cyclin D1 and D3 in pancreatic ductal adenocarcinoma. Mol Cancer. 2010;9:24.
Article
PubMed
PubMed Central
Google Scholar
Xia LJ, Wu YL, Ma J, Zhang FC. Therapeutic effects of antimicrobial peptide on malignant ascites in a mouse model. Mol Med Rep. 2018;17(5):6245–52.
CAS
PubMed
PubMed Central
Google Scholar
Zhou H, Cai Y, Liu D, et al. Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21(Waf1/Cip1) and p19(INK4d) upregulation in hepatocellular carcinoma. Cell Prolif. 2018;51(3):e12447.
Article
PubMed
PubMed Central
Google Scholar
Anastas JN, Zee BM, Kalin JH, et al. Re-programing chromatin with a bifunctional LSD1/HDAC inhibitor induces therapeutic differentiation in DIPG. Cancer Cell. 2019;36(5):528–44.
Article
CAS
PubMed
Google Scholar
Huang Y, Chen J, Lu C, et al. HDAC1 and Klf4 interplay critically regulates human myeloid leukemia cell proliferation. Cell Death Dis. 2014;5:e1491.
Article
CAS
PubMed
PubMed Central
Google Scholar
Li Y, Seto E. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harbor Perspect Med. 2016;6(10):a026831.
Article
Google Scholar
Rossi L, Battistelli C, de Turris V, et al. HDAC1 inhibition by MS-275 in mesothelial cells limits cellular invasion and promotes MMT reversal. Sci Rep. 2018;8(1):8492.
Article
PubMed
PubMed Central
Google Scholar
Yamaguchi T, Cubizolles F, Zhang Y, et al. Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. Genes Dev. 2010;24(5):455–69.
Article
CAS
PubMed
PubMed Central
Google Scholar
Senese S, Zaragoza K, Minardi S, et al. Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol. 2007;27(13):4784–95.
Article
CAS
PubMed
PubMed Central
Google Scholar
Vidal-Laliena M, Gallastegui E, Mateo F, Martinez-Balbas M, Pujol MJ, Bachs O. Histone deacetylase 3 regulates cyclin A stability. J Biol Chem. 2013;288(29):21096–104.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cha TL, Chuang MJ, Wu ST, et al. Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells. Clin Cancer Res: Off J Am Assoc Cancer Res. 2009;15(3):840–50.
Article
CAS
Google Scholar
Sonnemann J, Marx C, Becker S, et al. p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors. Br J Cancer. 2014;110(3):656–67.
Article
CAS
PubMed
Google Scholar
Ellis L, Bots M, Lindemann RK, et al. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood. 2009;114(2):380–93.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bajbouj K, Mawrin C, Hartig R, et al. P53-dependent antiproliferative and pro-apoptotic effects of trichostatin A (TSA) in glioblastoma cells. J Neurooncol. 2012;107(3):503–16.
Article
CAS
PubMed
Google Scholar